Market revenue in 2020 | USD 16.9 million |
Market revenue in 2028 | USD 43.0 million |
Growth rate | 12.4% (CAGR from 2020 to 2028) |
Largest segment | Neurological disorders |
Fastest growing segment | Cancer |
Historical data | 2016 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurological Disorders, Immunological Disorders, Hematology Diseases, Endocrine & Metabolism Diseases, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disease |
Key market players worldwide | Quest Diagnostics Inc, Centogene NV Ordinary Shares, Invitae Corp, Eurofins Scientific SE, PerkinElmer, Macrogenics Inc, Fulgent Genetics Inc, Myriad Genetics Inc, Labcorp Holdings Inc, OPKO Health Inc, 3billion, ARUP Laboratories, Strand Life Sciences, Ambry Genetics, REALM IDx, Inc., Baylor Genetics, Health Network Laboratories, PreventionGenetics, Biora Therapeutics, CooperSurgical, Artemis DNA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare disease genetic testing market will help companies and investors design strategic landscapes.
Neurological disorders was the largest segment with a revenue share of 15.98% in 2020. Horizon Databook has segmented the India rare disease genetic testing market based on neurological disorders, immunological disorders, hematology diseases, endocrine & metabolism diseases, cancer, musculoskeletal disorders, cardiovascular disorders, dermatology disease covering the revenue growth of each sub-segment from 2016 to 2028.
Absence of robust diagnostic and treatment facilities coupled with presence of a smaller number of trained genetic professionals are major setbacks that has slowed the revenue growth of this country. However, government bodies and healthcare organizations are playing significant role in shaping the India rare disease diagnosis landscape.
For instance, in January 2020, the Indian government announced to provide financial support under the umbrella scheme Rashtriya Arogaya Nidhi to patients with rare diseases. Similarly, the Indian Organization for Rare Diseases conducts conferences to discuss various issues occurring in providing improved services to patients with rare diseases.
Horizon Databook provides a detailed overview of country-level data and insights on the India rare disease genetic testing market , including forecasts for subscribers. This country databook contains high-level insights into India rare disease genetic testing market from 2016 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account